Nonetheless, limited data compared the impact of ASCT plus CART versus sequential CD19/CD20/CD22 or targeting other tumor antigen CAR T-cell therapy on advanced r/r CNS lymphoma. This evidence concerns the gene CD19 and primary central nervous system lymphoma.